Aspergillus Species Identification and Antifungal Resistance Mechanisms

Aspergillus species are ubiquitous moulds responsible for a spectrum of clinical syndromes, from allergic bronchopulmonary aspergillosis to life-threatening invasive disease in immunocompromised hosts. Accurate species identification underpins effective management, guiding choice of antifungal therapy and informing infection control. Traditional morphological and culture-based methods, while still important, often fail to distinguish cryptic or closely related species that differ in drug susceptibility. Molecular approaches—including multilocus gene sequencing, matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and whole-genome sequencing—have transformed taxonomy, uncovering hidden diversity and intrinsic resistance traits. Resistance mechanisms centre on alterations in the lanosterol 14α-demethylase gene (cyp51A and cyp51B), upregulation of efflux pumps and cell-membrane remodelling. Environmental and agricultural azole usage has selected for resistant genotypes that can be transmitted to humans, emphasising a One Health dimension. Together, these advances highlight the necessity of integrating precise diagnostics with antifungal stewardship to curb the global rise of resistant aspergillosis and optimise patient outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Aspergillus Species Identification and Antifungal Resistance Mechanisms publication trend

The graph below shows the total number of articles in aspergillus species identification and antifungal resistance mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Cryptic species: Morphologically similar but genetically distinct organisms that require molecular methods for accurate identification.

MALDI-TOF MS: A rapid proteomic technique using mass spectrometry to identify microorganisms by their protein “fingerprint.”

cyp51A gene: Encodes lanosterol 14α-demethylase, the enzyme targeted by azole antifungals; mutations confer drug resistance.

Azoles: A class of antifungal agents that inhibit ergosterol synthesis in fungal cell membranes.

Minimum inhibitory concentration (MIC): The lowest concentration of an antifungal that prevents visible growth of a microorganism in vitro.

References

1. What do We Know about Cryptic Aspergillosis?. Microorganisms (2024).
2. Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital. BMC Microbiology (2024).
3. Epidemiological characteristics of invasive Aspergillus isolates: Morphology, drug susceptibility, and mutations in azole drug targets. Journal of Infection and Public Health (2024).